Skip to main content
Erschienen in: Infection 5/2019

07.05.2019 | Original Paper

Influence of primary care antibiotic prescribing on incidence rates of multidrug-resistant Gram-negative bacteria in hospitalised patients

verfasst von: Munther S. Alnajjar, Mamoon A. Aldeyab, Michael G. Scott, Mary P. Kearney, Glenda Fleming, Fiona Glimore, David Farren, James C. McElnay

Erschienen in: Infection | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Use of antibiotics can give rise to the selection of resistant bacteria. It remains unclear whether antibiotic use in primary care can influence bacterial resistance incidence in patients when hospitalised. The aim of this study is to explore the impact of prior community antibiotic usage on hospital-detected multidrug-resistant Gram-negative (MRGN) incidence rate.

Methods

This pharmacoepidemiological study was case–control in design, and was carried out in the Antrim Area Hospital (N. Ireland) in two phases. In phase 1, the controls were matched according to: age, gender, admission ward, date of admission, and age-adjusted Charlson co-morbidity index score. During the second phase, controls were selected randomly from the total population of admissions to the hospital over the 2-year study period.

Results

In phase 1, multivariate analysis revealed that prior exposure to the second- and third-generation cephalosporins (p = 0.004) and fluoroquinolones (p = 0.023) in primary care was associated with an increased likelihood of MRGN detection in inpatients. In phase 2, an independent relationship between an increased risk of identification of MRGN, while hospitalised was associated with: prolonged hospitalisation (p < 0.001), being elderly (p < 0.001), being female (p = 0.007), and having genitourinary disease (p < 0.001).

Conclusion

This study provides clear evidence which supports the need to optimise antibiotic use in primary care to help reduce MRGN incidence in hospitalised patients.
Literatur
2.
Zurück zum Zitat Russell-Goldman E, Burke L, Humphreys H, Gilleece A, Fitzgerald-Hughes D, O’ Neill E. Clinical features and molecular epidemiology of extended-spectrum B-lactamases-producing Enterobacteriaceae: the hidden messages. J Med Microbiol. 2013;62:1768–74.CrossRef Russell-Goldman E, Burke L, Humphreys H, Gilleece A, Fitzgerald-Hughes D, O’ Neill E. Clinical features and molecular epidemiology of extended-spectrum B-lactamases-producing Enterobacteriaceae: the hidden messages. J Med Microbiol. 2013;62:1768–74.CrossRef
3.
Zurück zum Zitat Siedelman L, Kline L, Duval S. Risk factors for community- and health facility–acquired extended-spectrum β-lactamase–producing bacterial infections in patients at the University of Minnesota Medical Center, Fairview. Am J Infect Control. 2013;40:849–54.CrossRef Siedelman L, Kline L, Duval S. Risk factors for community- and health facility–acquired extended-spectrum β-lactamase–producing bacterial infections in patients at the University of Minnesota Medical Center, Fairview. Am J Infect Control. 2013;40:849–54.CrossRef
4.
Zurück zum Zitat Rogers BA. (on behalf of the Australasian Society for Infectious Diseases Clinical Research Network) Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother. 2014;58:2126–34.CrossRef Rogers BA. (on behalf of the Australasian Society for Infectious Diseases Clinical Research Network) Community-onset Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. Antimicrob Agents Chemother. 2014;58:2126–34.CrossRef
5.
Zurück zum Zitat Rodríguez-Baño J. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2008;14:180–4.CrossRef Rodríguez-Baño J. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2008;14:180–4.CrossRef
6.
Zurück zum Zitat Branger C, Ledda A, Billard-Pomares T, Doublet B, Fouteau S, Barbe V, Roche D, et al. Extended-spectrum β-lactamase-encoding genes are spreading on a wide range of Escherichia coli plasmids existing prior to the use of third-generation cephalosporins. Microb Genom. 2018;4:85. https://doi.org/10.1099/mgen.0.000203 (Epub Aug 2018).CrossRef Branger C, Ledda A, Billard-Pomares T, Doublet B, Fouteau S, Barbe V, Roche D, et al. Extended-spectrum β-lactamase-encoding genes are spreading on a wide range of Escherichia coli plasmids existing prior to the use of third-generation cephalosporins. Microb Genom. 2018;4:85. https://​doi.​org/​10.​1099/​mgen.​0.​000203 (Epub Aug 2018).CrossRef
7.
Zurück zum Zitat Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena G, et al. Community-onset bacteraemia due to extended spectrum B-lactamase-producing E. coli: risk factors and prognosis. Clin Infect Dis. 2010;50:40–8.CrossRef Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena G, et al. Community-onset bacteraemia due to extended spectrum B-lactamase-producing E. coli: risk factors and prognosis. Clin Infect Dis. 2010;50:40–8.CrossRef
8.
Zurück zum Zitat Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum- lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother. 2011;66:1383–8.CrossRef Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum- lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother. 2011;66:1383–8.CrossRef
9.
Zurück zum Zitat Oli AN, Eze DE, Gugu TH, Ezeobi I, Maduagwu UN, Ihekwereme CP. Multi-antibiotic resistant extended-spectrum beta-lactamase producing bacteria pose a challenge to the effective treatment of wound and skin infections. Pan Afr Med J. 2017;27:66.PubMedPubMedCentral Oli AN, Eze DE, Gugu TH, Ezeobi I, Maduagwu UN, Ihekwereme CP. Multi-antibiotic resistant extended-spectrum beta-lactamase producing bacteria pose a challenge to the effective treatment of wound and skin infections. Pan Afr Med J. 2017;27:66.PubMedPubMedCentral
10.
Zurück zum Zitat Artero A, Esparcia A, Alberola J, Madrazo M, Nogueira JM, Eiros JM. Prospective cohort study of risk factors for extended-spectrum ß-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital. Int J Clin Pract. 2017;71:e13001 (Epub 5 Sep 2017).CrossRef Artero A, Esparcia A, Alberola J, Madrazo M, Nogueira JM, Eiros JM. Prospective cohort study of risk factors for extended-spectrum ß-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital. Int J Clin Pract. 2017;71:e13001 (Epub 5 Sep 2017).CrossRef
11.
Zurück zum Zitat Steiger SN, Comito RR, Nicolau DP. Clinical and economic implications of urinary tract infections. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17:377–83.CrossRef Steiger SN, Comito RR, Nicolau DP. Clinical and economic implications of urinary tract infections. Expert Rev Pharmacoeconomics Outcomes Res. 2017;17:377–83.CrossRef
12.
Zurück zum Zitat Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.CrossRef Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.CrossRef
13.
Zurück zum Zitat Kang C, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song J. Outcomes and risk factors for mortality in community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis. 2013;45:519–25.CrossRef Kang C, Wi YM, Ko KS, Chung DR, Peck KR, Lee NY, Song J. Outcomes and risk factors for mortality in community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy. Scand J Infect Dis. 2013;45:519–25.CrossRef
14.
Zurück zum Zitat Castillo-Tokumori F, Irey-Salgado C, Málaga G. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2017;55:16–9.CrossRef Castillo-Tokumori F, Irey-Salgado C, Málaga G. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. Int J Infect Dis. 2017;55:16–9.CrossRef
15.
Zurück zum Zitat Cooper BS, Medley GF, Stone SP. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci. 2004;101:10223–8.CrossRef Cooper BS, Medley GF, Stone SP. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci. 2004;101:10223–8.CrossRef
16.
Zurück zum Zitat Gallini A, Degris A, Desplas M, Bourrel R, Archambaud M, Montastruc JL, et al. Inlfluence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother. 2010;65:2650–8.CrossRef Gallini A, Degris A, Desplas M, Bourrel R, Archambaud M, Montastruc JL, et al. Inlfluence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother. 2010;65:2650–8.CrossRef
17.
Zurück zum Zitat Lopez-Lozano JM, Monnet DL, Yague A, Burgos A, Gonzalo N, Campillos P, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use a time-series analysis. Int J Antimicrob Agents. 2000;14:21–31.CrossRef Lopez-Lozano JM, Monnet DL, Yague A, Burgos A, Gonzalo N, Campillos P, et al. Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use a time-series analysis. Int J Antimicrob Agents. 2000;14:21–31.CrossRef
18.
Zurück zum Zitat Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74:171–9.CrossRef Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74:171–9.CrossRef
19.
Zurück zum Zitat Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria. GMS Hyg Infect Control. 2017;12:1–24. Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria. GMS Hyg Infect Control. 2017;12:1–24.
20.
Zurück zum Zitat Ramiarina RA, Ramiarina BL, Almeida RM. Pereira WCD Comorbidity adjustment index for the international classification of diseases, 10th revision. Revista de Saúde Pública. 2008;42:590–7.CrossRef Ramiarina RA, Ramiarina BL, Almeida RM. Pereira WCD Comorbidity adjustment index for the international classification of diseases, 10th revision. Revista de Saúde Pública. 2008;42:590–7.CrossRef
21.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–82.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–82.CrossRef
24.
Zurück zum Zitat Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe J, Sordillo EM, et al. Community-associated extended-spectrum beta-lactamase-producing E. coli infection in the United State. Clin Infect Dis. 2013;56:641–8.CrossRef Doi Y, Park YS, Rivera JI, Adams-Haduch JM, Hingwe J, Sordillo EM, et al. Community-associated extended-spectrum beta-lactamase-producing E. coli infection in the United State. Clin Infect Dis. 2013;56:641–8.CrossRef
25.
Zurück zum Zitat Livermore DM. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother. 2013;68:2667–8.CrossRef Livermore DM. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother. 2013;68:2667–8.CrossRef
26.
Zurück zum Zitat Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis. 2016;63:310–8.CrossRef Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis. 2016;63:310–8.CrossRef
28.
Zurück zum Zitat Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Béchet S, et al. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016;71:2949–57.CrossRef Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Béchet S, et al. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016;71:2949–57.CrossRef
29.
Zurück zum Zitat D’Agata EM. Methodological issues of case-control studies: a review of established and newly recognised limitations. Infect Control Hosp Epidemiol. 2005;26:338–41.CrossRef D’Agata EM. Methodological issues of case-control studies: a review of established and newly recognised limitations. Infect Control Hosp Epidemiol. 2005;26:338–41.CrossRef
30.
Zurück zum Zitat MacDougall C, Powell J, Johnson C, Edmond M, Polk R. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–6.CrossRef MacDougall C, Powell J, Johnson C, Edmond M, Polk R. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435–6.CrossRef
31.
Zurück zum Zitat Vernaz N, Huttner B, Muscionico D, Salomon JL, Bonnabry P, Lopez-Lozano JM, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-bases data from a large hospital and its surrounding community. J Antimicrob Chemother. 2011;66:928–37.CrossRef Vernaz N, Huttner B, Muscionico D, Salomon JL, Bonnabry P, Lopez-Lozano JM, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population-bases data from a large hospital and its surrounding community. J Antimicrob Chemother. 2011;66:928–37.CrossRef
32.
Zurück zum Zitat Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, et al. Clinical risk score for prediction of extended-spectrum β-lactamase-producing enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol. 2017;38:266–7.CrossRef Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, et al. Clinical risk score for prediction of extended-spectrum β-lactamase-producing enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol. 2017;38:266–7.CrossRef
33.
Zurück zum Zitat Crogan N, Evans BC. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs. 2007;28:161–5.CrossRef Crogan N, Evans BC. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs. 2007;28:161–5.CrossRef
34.
Zurück zum Zitat Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Ann Rev Microbiol. 2011;65:501–20.CrossRef Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Ann Rev Microbiol. 2011;65:501–20.CrossRef
35.
Zurück zum Zitat Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, et al. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: evaluation of PES pathogens. J Infect Chemother. 2017;23:23–6.CrossRef Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, et al. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: evaluation of PES pathogens. J Infect Chemother. 2017;23:23–6.CrossRef
36.
Zurück zum Zitat Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. Pharmacotherapy handbook. 7th ed. Maidenheach: McGraw-Hill Medical; 2008. p. 544–55. Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. Pharmacotherapy handbook. 7th ed. Maidenheach: McGraw-Hill Medical; 2008. p. 544–55.
37.
Zurück zum Zitat Pérez Heras I, Sanchez-Gomez JC, Beneyto-Martin P, Ruano-de-Pablo L, Losada-Pinedo B. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: prevalence, risk factors, and resistances. Medicine (Baltimore). 2017;96:e8571.CrossRef Pérez Heras I, Sanchez-Gomez JC, Beneyto-Martin P, Ruano-de-Pablo L, Losada-Pinedo B. Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016: prevalence, risk factors, and resistances. Medicine (Baltimore). 2017;96:e8571.CrossRef
Metadaten
Titel
Influence of primary care antibiotic prescribing on incidence rates of multidrug-resistant Gram-negative bacteria in hospitalised patients
verfasst von
Munther S. Alnajjar
Mamoon A. Aldeyab
Michael G. Scott
Mary P. Kearney
Glenda Fleming
Fiona Glimore
David Farren
James C. McElnay
Publikationsdatum
07.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 5/2019
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01305-6

Weitere Artikel der Ausgabe 5/2019

Infection 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.